-
Mashup Score: 4A new standard of care for advanced-stage urothelial carcinoma - 2 month(s) ago
Nature Reviews Clinical Oncology – A new standard of care for advanced-stage urothelial carcinoma
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges - 2 month(s) ago
Nature Reviews Clinical Oncology – The composition of the gut microbiota has emerged as a tumour-extrinsic factor that modulates response to immune-checkpoint inhibitors (ICIs), although the lack…
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 91FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions - 2 month(s) ago
Nature Reviews Clinical Oncology – FGFR inhibitors are now approved for use in patients with advanced-stage urothelial carcinoma, cholangiocarcinoma and myeloid or lymphoid neoplasms that harbour…
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 23FDA approvals in 2023: biomarker-positive subsets, equipoise and verification of benefit - Nature Reviews Clinical Oncology - 3 month(s) ago
In 2023, the US FDA approved several new cancer drugs and biologic agents, including seven small-molecule inhibitors, four bispecific T cell engagers, two anti-PD-1 antibodies and one cell therapy product. Regulatory focus areas included analyses of biomarker-positive subgroups that drive efficacy, equipoise in randomized controlled trials and a new authority to require confirmatory trials be…
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 23FDA approvals in 2023: biomarker-positive subsets, equipoise and verification of benefit - Nature Reviews Clinical Oncology - 3 month(s) ago
In 2023, the US FDA approved several new cancer drugs and biologic agents, including seven small-molecule inhibitors, four bispecific T cell engagers, two anti-PD-1 antibodies and one cell therapy product. Regulatory focus areas included analyses of biomarker-positive subgroups that drive efficacy, equipoise in randomized controlled trials and a new authority to require confirmatory trials be…
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10
Nature Reviews Clinical Oncology – Adjuvant chemotherapy improves OS in UTUC
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet-
New data suggest that adjuvant platinum-based chemotherapy improves not only DFS but also OS in pts with muscle-invasive or locally advanced upper tract urothelial carcinoma (of the ureter or renal pelvis), supporting this approach as the standard of care: https://t.co/zS0UQo6rOy https://t.co/ewOXQjCQO5
-
-
Mashup Score: 22FDA approvals in 2023: biomarker-positive subsets, equipoise and verification of benefit - Nature Reviews Clinical Oncology - 3 month(s) ago
In 2023, the US FDA approved several new cancer drugs and biologic agents, including seven small-molecule inhibitors, four bispecific T cell engagers, two anti-PD-1 antibodies and one cell therapy product. Regulatory focus areas included analyses of biomarker-positive subgroups that drive efficacy, equipoise in randomized controlled trials and a new authority to require confirmatory trials be…
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 29
Ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR) is a mediator of the cellular replication stress response that, upon activation, initiates a cascade of coordinated reactions that ultimately enables DNA repair. This biological function makes ATR an attractive therapeutic target in cancers with elevated replication stress or DNA-repair deficiency. This Review discusses…
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 75KN046 shows tolerability and activity in TNBC - 3 month(s) ago
Nature Reviews Clinical Oncology – KN046 shows tolerability and activity in TNBC
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Tabelecleucel is effective in EBV-positive lymphoproliferative disease - Nature Reviews Clinical Oncology - 3 month(s) ago
Nature Reviews Clinical Oncology – Tabelecleucel is effective in EBV-positive lymphoproliferative disease
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet-
In a Research Highlight now published online, we discuss the results of the ALLELE trial, which led to the approval of tabelecleucel for the treatment of relapsed and/or refractory EBV-positive post-transplant lymphoproliferative disease by the @EMA_News https://t.co/eYLmIgpLv3 https://t.co/ALhxQJs366
-
In a Research Highlight now published online, we discuss the results of the EV-302 trial of enfortumab vedotin + pembrolizumab versus platinum-based chemo in advanced-stage urothelial carcinoma https://t.co/NOi0i7HPDp https://t.co/3uWF8a8QII